



Figure 1 Skin tumors covering whole body of the patient just before RI-UCBT (a). Skin tumors of the patient had disappeared in 90 days after RI-UCBT (b).

sustained CR so that he had enough time to return to his job. Although CB has been shown to have functionally immature immune cells, it showed its extremely powerful anti-leukemic activity even from the early period post transplant, as the patient's skin lesion had never disappeared during induction chemotherapy including high-dose Ara-C.

Whether the clinical course of this case can be applicable to all aged patients or this is exceptional case needs to be investigated carefully. The indication of allo-SCT for those who are elderly has to be determined individually with extremely careful and repeated discussion with patients, families and transplant staff. Nevertheless, the indication of allo-SCT should not be determined by age as a sole factor. Otherwise, elderly patients may lose chance of cure or good disease control, by not performing toxic yet powerful treatment, such as transplant.

Conflict of interest

The authors declare no conflict of interest.

K Masuoka¹, N Uchida¹, K Ishiwata¹, S Takagi¹, M Tsuji¹, H Yamamoto¹, S Seo¹, N Matsuno¹, A Wake¹, S Makino², A Yoneyama³ and S Taniguchi¹

¹Department of Hematology, Toranomon Hospital, Tokyo, Japan;

²Department of Transfusion Medicine, Toranomon Hospital, Tokyo, Japan and

³Department of Infectious Diseases, Toranomon Hospital, Tokyo, Japan
E-mail: masuoka@mishuku.gr.jp

References

1 Deschler B, Lubbert M. Acute myeloid leukemia: epidemiology and etiology. *Cancer* 2006; **107**: 2099–2107.

- 2 Ringden O, Horowitz MM, Gale RP, Biggs JC, Gajewski J, Rimm AA *et al*. Outcome after allogeneic bone marrow transplant for leukemia in older adults. *JAMA* 1993; **270**: 57–60.
- 3 Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G *et al*. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. *Blood* 1998; **91**: 756–763.
- 4 Laughlin MJ, Eapen M, Rubinstein P, Wagner JE, Zhang MJ, Champlin RE *et al*. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. *N Engl J Med* 2004; **351**: 2265–2275.
- 5 Rocha V, Labopin M, Sanz G, Arcese W, Schwerdtfeger R, Bosi A *et al*. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. *N Engl J Med* 2004; **351**: 2276–2285.
- 6 Barker JN, Weisdorf DJ, DeFor TE, Blazar BR, Miller JS, Wagner JE. Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. *Blood* 2003; **102**: 1915–1919.
- 7 Miyakoshi S, Yuji K, Kami M, Kusumi E, Kishi Y, Kobayashi K *et al*. Successful engraftment after reduced-intensity umbilical cord blood transplantation for adult patients with advanced hematological diseases. *Clin Cancer Res* 2004; **10**: 3586–3592.
- 8 Kishi Y, Kami M, Miyakoshi S, Kanda Y, Murashige N, Teshima T *et al*. Early immune reaction after reduced-intensity cord-blood transplantation for adult patients. *Transplantation* 2005; **80**: 34–40.
- 9 Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG *et al*. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. *Blood* 2005; **106**: 2912–2919.
- 10 Uchida N, Wake A, Takagi S, Yamamoto H, Kato D, Matsushashi Y *et al*. Umbilical cord blood transplantation after reduced-intensity conditioning for elderly patients with hematologic diseases. *Biol Blood Marrow Transplant* 2008; **14**: 583–590.

